跳至主要内容
临床试验/NCT00822367
NCT00822367已完成不适用

Assessment of Glycemic Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes Mellitus

Walter Reed Army Medical Center0 个研究点目标入组 19 人开始时间: 2006年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
19
主要终点
To determine the nutritional supplements glycemic response in patients with DM, defined as the maximum glucose excursion, area under the curve, and 2 and 3 hour BG levels fol

研究概览

简要总结

The purpose of the study is to determine which of the commonly used meal supplements is the best product for patients with DM. This is important because meal supplements are becoming more popular as meal replacements in the United States. Peak blood sugar occurs about 2 hours later after a meal. Therefore, the best product would be the one that produces a smallest rise in blood sugar.

详细描述

The purpose of the study is to determine which of the commonly used commercial nutritional supplements are preferential for patients with Diabetes Mellitus (DM). We will compare the post-prandial blood glucose (BG) responses in response to 3 different nutritional supplements each containing 50 grams of carbohydrate in adult patients with type 2 diabetes mellitus and relate these responses to one of the two well-recognized indices of insulin sensitivity - HOMA-R and QUICKI.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 18-75 years
  • Type-2 diabetes mellitus for over 3 months
  • A1c of 7.0 - 10.0% within the past 3 months
  • Controlled with diet /exercise and/or on oral anti-diabetic agents which are non-insulin secretatgogues, i.e. Metformin and/or Pioglitazone
  • Able to give informed consent
  • Expected to be in the DC metropolitan for the duration of the study
  • Fasting blood glucose between 70 and 250 mg/dl

排除标准

  • Patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (Symlin), GLP-1 analogs (Byetta), insulin, or alpha-glycosidase inhibitors
  • A1c under 7.0% or over 10.0%
  • Fasting blood glucose < 70 or > 250 mg/d
  • Gastrointestinal disorders affecting digestion and absorption of nutrients such as lactose intolerance, chronic diarrhea, pancreatic insufficiency.
  • Clinical history of documented gastroperesis.
  • Patients on hemodialysis or peritoneal dialysis
  • Pregnancy
  • Inability to read and/or speak English

结局指标

主要结局

To determine the nutritional supplements glycemic response in patients with DM, defined as the maximum glucose excursion, area under the curve, and 2 and 3 hour BG levels fol

时间窗: BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement.

次要结局

未报告次要终点

研究者

申办方类型
Fed

相似试验

Blood Sugar Response to Commercial Nutritional... | 临床试验